- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06829914
Shockwave ™ vs endarterectomia cirúrgica para estenose da artéria femoral comum grave calcificada: comparação de eficácia, segurança e resultados de longo prazo (Shockify)
The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. The study will challenge the current guideline that recommends common femoral endarterectomy (CFE) as the primary treatment for symptomatic CFA stenosis.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
This is a pilot, prospective, randomized clinical trial. This trial compares patients with severe symptomatic moderate to severe calcified CFA stenosis undergoing traditional gold standard CFA endarterectomy to innovative technique of endovascular treatment using Shockwave™ Intra vascular Lithotripsy (IVL) using M5+ balloon with Drug coated balloon to achieve removal and debulking of plaque and achieve luminal gain. Patients who meet inclusion criteria will be informed and consented by a clinical coordinator if they wish to participate in the trial. If participants are candidates for surgery, they will then be randomized into one of two cohorts, receiving either Shockwave™ IVL + DCB (drug-coated balloon) procedure or a standard surgical endarterectomy. The study compares the 1-year efficacy and 6-month safety outcomes post-procedure for patients with severe, symptomatic CFA stenosis receiving Shockwave™ IVL with DCB versus surgical endarterectomy.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Texas
-
Plano, Texas, Estados Unidos, 75093
- Baylor Scott & White The Heart Hospital - Plano
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab):
- CFA atherosclerotic stenosis 60-100%
- Moderate to severe calcification reported on imaging
- Lifestyle-limiting intermittent claudication (IC) or chronic limb-threatening ischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5
- Failing conservative therapy
- Operative candidate for CFE prior to enrollment
- ≥18 years of age
Exclusion Criteria:
A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:
- History of CFE or bypass in affected limb
- Thrombosis of affected CFA
- Aneurysm in the common femoral artery of target limb
- Known target lesion restenosis (re-narrowing of the artery to ≥50% following the alleviation of a previous narrowing within 3 months)
- Any preceding percutaneous cardiovascular intervention within 2 weeks
- Inability to tolerate DAPT
- Known coagulopathy or bleeding diathesis, thrombocytopenia with platelet count <100,000/µL
- Uncontrolled diabetes (HbA1c ≥10.0%)
- Non-ambulatory
- Extensive tissue loss requiring amputation or salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputations
- MI within 6 weeks (defined as presumed ischemic symptoms (chest pain, ST-segment deviation and troponin higher than 2 times the upper limit of normal))
- Stroke within 3 months (defined as sudden transient or irreversible focal neurological deficit resulting from a cerebrovascular cause)
- Pregnant
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Shockwave Catheter
Shockwave™ Intravenous Lithotripsy (IVL)+ DCB (Drug Coated Balloon) |
Shockwave™ IVL + DCB procedure |
|
Comparador Ativo: surgical endarterectomy
Surgery should be performed with patch angioplasty, with or without profunda femoris endarterectomy. |
Standard CFA endarterectomy |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Revascularização da lesão-alvo clinicamente acionada (CDTLR (revascularização repetida de sintomas da lesão do índice))))
Prazo: Data do procedimento até 1 ano de pós-operatório
|
Data do procedimento até 1 ano de pós-operatório
|
|
|
Restenose a ≥ 50% da lesão-alvo em angiografia ou ultrassom de acompanhamento
Prazo: Data do procedimento até 1 ano de pós-operatório
|
Data do procedimento até 1 ano de pós-operatório
|
|
|
Liberdade da morte perioperatória
Prazo: Data do procedimento até 30 dias após a opção
|
Data do procedimento até 30 dias após a opção
|
|
|
Liberdade dos principais eventos cardiovasculares adversos (Mace (AVC, infarto do miocárdio (MI), morte cardiovascular))
Prazo: Data do procedimento até 30 dias após a opção
|
Data do procedimento até 30 dias após a opção
|
|
|
Freedom from major adverse events
Prazo: Procedure date through 6 months post-op
|
|
Procedure date through 6 months post-op
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mortalidade
Prazo: Data do procedimento até 1 ano de pós-operatório
|
Data do procedimento até 1 ano de pós-operatório
|
|
|
Transfusão de sangue intraoperatória> 4 minutos
Prazo: Intra-op
|
Intra-op
|
|
|
Duração processual (minutos)
Prazo: Intra-op
|
Intra-op
|
|
|
Duração da estadia (dias)
Prazo: Data do procedimento até 1 ano após a opção
|
Data do procedimento até 1 ano após a opção
|
|
|
Anemia pós -operatória que requer transfusão de sangue
Prazo: Data do procedimento até 30 dias após a opção
|
Data do procedimento até 30 dias após a opção
|
|
|
Readmissões
Prazo: 30 dias após a operação, 30 dias após a descarga
|
30 dias após a operação, 30 dias após a descarga
|
|
|
Voltar à sala de operações / suíte de angiografia
Prazo: 30 dias após a operação
|
30 dias após a operação
|
|
|
Rutherford Chronic Limb Ischemia (CLI) Category
Prazo: 30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
|
https://www.ncbi.nlm.nih.gov/books/NBK553864/table/ch20.Tab2/# Stage 0 - Asymptomatic. Stage 1 - Mild claudication - Completes treadmill exercise; Ankle Pressure (AP) after exercise >50 mmHg but at least 20 mmHg lower than resting value. Stage 2 - Moderate claudication - Between categories 1 and 3. Stage 3 - Severe claudication - Cannot complete standard treadmill exercise and AP after exercise <50 mm Hg. Stage 4 - Ischemic rest pain - Resting AP <40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); Toe Pressure (TP) < 30 mm Hg. Stage 5 - Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal ischemia- Resting AP < 60 mm Hg, ankle or metatarsal PVR flat or barely pulsatile; TP < 40 mm Hg Stage 6 - Major tissue loss-extending above TM level, functional foot no longer salvageable - Same as category 5 |
30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
|
|
Treatment satisfaction and quality of life (PAQ)
Prazo: Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
|
Measured by the Peripheral Artery Questionnaire (PAQ), a 20-question questionnaire measuring peripheral vascular disease affect on quality of life. Questionnaires may be completed in-person or via phone call conducted by the study coordinator. |
Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
|
|
Access/surgical site complications
Prazo: 30 days post-op, 6 months post-op
|
|
30 days post-op, 6 months post-op
|
|
Pneumonia (number of cases)
Prazo: Procedure date through 30 days post-op
|
Patients must meet criteria from both sections: Radiology: One definitive chest radiological exam (x-ray or CT) with at least one of the following:
Patients with underlying pulmonary or cardiac disease require two serial chest radiological exams (x-ray or CT) taken no less than 12 hours apart, but no more than 7 days apart. Signs/Symptoms/Laboratory: at least one of the following:
|
Procedure date through 30 days post-op
|
|
Prolonged intubation
Prazo: Procedure date through 30 days post-op
|
Intubation greater than 48 hours postoperatively |
Procedure date through 30 days post-op
|
|
Urinary tract infection
Prazo: Procedure date through 30 days post-op
|
Must meet one of the following TWO criteria within 30 days of the operation:
AND urine culture of >105 colonies/mL urine with no more than two species of organisms OR two of the following:
AND any of the following:
|
Procedure date through 30 days post-op
|
|
Sepsis
Prazo: Procedure date through 30 days post-op
|
The disorder spectrum spans from relatively mild physiologic abnormalities to septic shock. The most significant level is reported using the following criteria: SIRS (Systemic Inflammatory Response Syndrome), clinically recognized by the presence of two or more of the following in the same time frame: Temp >38 degrees C or 90 bpm RR >20 breaths/min or PaCO2 12,000 cell/mm3, 10% immature (band) forms anion gap acidosis. Report if the patient has clinical signs and symptoms of SIRS listed above and meets either A or B: A. One of the following:
B. Suspected pre-operative infection or bowel infarction leading to the surgical procedure. Procedural findings must confirm this suspected diagnosis with one or more of the following:
|
Procedure date through 30 days post-op
|
|
Septic shock
Prazo: Procedure date through 30 days post-op
|
Report this variable if the patient has sepsis AND documented organ and/or circulatory dysfunction. Examples of organ dysfunction include: oliguria, acute alteration in mental status, acute respiratory distress. Examples of circulatory dysfunction include: hypotension, requirement of inotropic or vasopressor agents. The presence of pneumatosis along with the presence of SIRS is assigned. |
Procedure date through 30 days post-op
|
|
Graft failure
Prazo: Procedure date through 30 days post-op
|
Mechanical failure of an extracardiac graft or prosthesis including myocutaneous flaps and skin grafts requiring return to the operating room, interventional radiology or a balloon angioplasty within 30 days of the operation. |
Procedure date through 30 days post-op
|
|
Cardiac arrest
Prazo: Procedure date through 30 days post-op
|
The absence of cardiac rhythm or presence of chaotic cardiac rhythm, intraoperatively or postoperatively, which results in a cardiac arrest requiring the initiation of CPR, which includes chest compressions. Patients are included who are in a pulseless VT or Vfib in in which defibrillation is performed and PEA arrests requiring chest compressions. Patients with automated implantable cardioverter defibrillator (AICD) that fire but the patient has no loss of consciousness should be excluded. |
Procedure date through 30 days post-op
|
|
Myocardial infarction
Prazo: Procedure date through 30 days post-op
|
Documentation of one or more of the following changes indicative of acute MI:
|
Procedure date through 30 days post-op
|
|
Acute kidney injury
Prazo: Procedure date through 30 days post-op
|
In a patient who did not require dialysis preoperatively, worsening of renal dysfunction postoperatively requiring hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or ultrafiltration |
Procedure date through 30 days post-op
|
|
Dialysis
Prazo: Procedure date through 30 days post-op
|
Initiation of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or ultrafiltration in a patient not previously on said therapy preoperatively |
Procedure date through 30 days post-op
|
|
Deep vein thrombosis
Prazo: Procedure date through 30 days post-op
|
New diagnosis of blood clot or thrombus within the venous system (superficial or deep) which may be coupled with inflammation and requires treatment. Must be noted within 30 days after the principal operative procedure AND one of the following A or B below: A.New Diagnosis of a [new] venous thrombosis (superficial or deep), confirmed by a duplex, venogram, CT scan, or any other definitive imaging modality (including direct pathology examination such as autopsy) AND the patient must be treated with anticoagulation therapy and/or placement of a vena cava filter or clipping of the vena cava, or the record indicates that treatment was warranted but there was no additional appropriate treatment option available. B. As per (A) above, but the patient or decisionmaker has refused treatment. There must be documentation in the medical record of the [patient's] refusal of treatment. |
Procedure date through 30 days post-op
|
|
Pulmonary embolism
Prazo: Procedure date through 30 days post-op
|
Lodging of a blood clot in the pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma. The blood clots usually originate from the deep leg veins or pelvic venous system. Since there are not always preoperative studies proving that a clot or thrombus was not present preoperatively, the technical specification of the variable requires only a "new diagnosis"- in other words the clot or thrombus was not previously known. A pulmonary embolism must be noted within 30 days after the principal operative procedure AND the following criteria, A AND B below: A. New diagnosis of a new blood clot in a pulmonary artery AND B. The patient has a V-Q scan interpreted as high probability of pulmonary embolism or a positive CT exam, TEE, pulmonary arteriogram, CT angiogram, or any other definitive imaging modality (including direct pathology examination such as autopsy |
Procedure date through 30 days post-op
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sameh Sayfo, MD, Baylor Scott & White The Heart Hospital - Plano
- Investigador principal: John Kedora, MD, Baylor Scott & White The Heart Hospital - Plano
Publicações e links úteis
Publicações Gerais
- Adams G, Shammas N, Mangalmurti S, Bernardo NL, Miller WE, Soukas PA, Parikh SA, Armstrong EJ, Tepe G, Lansky A, Gray WA. Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. J Endovasc Ther. 2020 Jun;27(3):473-480. doi: 10.1177/1526602820914598. Epub 2020 Apr 3.
- Stavroulakis K, Schwindt A, Torsello G, Beropoulis E, Stachmann A, Hericks C, Bollenberg L, Bisdas T. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease. J Endovasc Ther. 2018 Feb;25(1):92-99. doi: 10.1177/1526602817748319. Epub 2017 Dec 18.
- Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, Wolf F, Jaff M, Lansky A, Zeller T. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019 Feb 1;93(2):335-342. doi: 10.1002/ccd.27943. Epub 2018 Nov 25.
- Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004 Feb;147(2):301-8. doi: 10.1016/j.ahj.2003.08.001.
- Brodmann M, Werner M, Brinton TJ, Illindala U, Lansky A, Jaff MR, Holden A. Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery Lesions. J Am Coll Cardiol. 2017 Aug 15;70(7):908-910. doi: 10.1016/j.jacc.2017.06.022. No abstract available.
- Adams G, Soukas PA, Mehrle A, Bertolet B, Armstrong EJ. Intravascular Lithotripsy for Treatment of Calcified Infrapopliteal Lesions: Results from the Disrupt PAD III Observational Study. J Endovasc Ther. 2022 Feb;29(1):76-83. doi: 10.1177/15266028211032953. Epub 2021 Aug 12.
- Tepe G, Brodmann M, Werner M, Bachinsky W, Holden A, Zeller T, Mangalmurti S, Nolte-Ernsting C, Bertolet B, Scheinert D, Gray WA; Disrupt PAD III Investigators. Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial. JACC Cardiovasc Interv. 2021 Jun 28;14(12):1352-1361. doi: 10.1016/j.jcin.2021.04.010.
- Kang JL, Patel VI, Conrad MF, Lamuraglia GM, Chung TK, Cambria RP. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg. 2008 Oct;48(4):872-7. doi: 10.1016/j.jvs.2008.05.025. Epub 2008 Jul 17.
- Kuma S, Tanaka K, Ohmine T, Morisaki K, Kodama A, Guntani A, Ishida M, Okazaki J, Mii S. Clinical Outcome of Surgical Endarterectomy for Common Femoral Artery Occlusive Disease. Circ J. 2016;80(4):964-9. doi: 10.1253/circj.CJ-15-1177. Epub 2016 Feb 19.
- Nguyen BN, Amdur RL, Abugideiri M, Rahbar R, Neville RF, Sidawy AN. Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015 Jun;61(6):1489-94.e1. doi: 10.1016/j.jvs.2015.01.024. Epub 2015 Feb 19.
- Shammas NW, Abi Doumet A, Karia R, Khalafallah R. An Overview of the Treatment of Symptomatic Common Femoral Artery Lesions with a Focus on Endovascular Therapy. Vasc Health Risk Manag. 2020 Feb 20;16:67-73. doi: 10.2147/VHRM.S242291. eCollection 2020.
- Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, Roffi M, Dorsaz PA, Schwarzwalder U, Burgelin K, Macharzina R, Zeller T. Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011 Aug 16;58(8):792-8. doi: 10.1016/j.jacc.2011.01.070.
- Linni K, Ugurluoglu A, Hitzl W, Aspalter M, Holzenbein T. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial. J Endovasc Ther. 2014 Aug;21(4):493-502. doi: 10.1583/14-4699R.1.
- Garcia LA, Lyden SP. Atherectomy for infrainguinal peripheral artery disease. J Endovasc Ther. 2009 Apr;16(2 Suppl 2):II105-15. doi: 10.1583/08-2656.1.
- Baig M, Kwok M, Aldairi A, Imran HM, Khan MS, Moustafa A, Hyder ON, Saad M, Aronow HD, Soukas PA. Endovascular Intravascular Lithotripsy in the Treatment of Calcific Common Femoral Artery Disease: A Case Series With an 18-Month Follow-Up. Cardiovasc Revasc Med. 2022 Oct;43:80-84. doi: 10.1016/j.carrev.2022.05.003. Epub 2022 May 7.
- Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, Shishehbor MH, Holden AH, Bajakian DR, Garcia LA, Kum SWC, Rundback J, Armstrong E, Lee JK, Khatib Y, Weinberg I, Garcia-Garcia HM, Ruster K, Teraphongphom NT, Zheng Y, Wang J, Jones-McMeans JM, Parikh SA; LIFE-BTK Investigators. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med. 2024 Jan 4;390(1):9-19. doi: 10.1056/NEJMoa2305637. Epub 2023 Oct 25.
- Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 021-263
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .